Therefore, multikinase inhibitors (MKIs) that target multiple tyrosine kinase receptors, including RET and those involved in angiogenesis, such as VEGFRs and PDGFRs, were initially used to treat advanced RET-mutated MTC and subsequently other RET-altered cancers (55, 56). This evidence concerns the gene RET and medullary thyroid gland carcinoma.